" /> Danoprevir - CISMeF





Preferred Label : Danoprevir;

NCIt definition : An orally bioavailable, peptidomimetic inhibitor of hepatitis C virus (HCV) NS3/4A protease, with antiviral activity against HCV and potential antiviral activity against SARS-CoV-2. Upon oral administration, danoprevir binds to and blocks the activity of HCV NS3/4A protease. This prevents the cleavage and processing of HCV viral proteins leading to the inhibition of HCV replication. Danoprevir may also bind to and block of the activity of SARS-CoV-2 protease. This prevents the cleavage and processing of SARS-CoV-2 viral proteins leading to the inhibition of SARS-CoV-2 replication. NS3/4A, a chymotrypsin-like serine protease, is responsible for cleavage at four sites of the HCV polyprotein to form the viral proteins required for HCV replication. It plays a key role in the HCV viral replication process. HCV infection is associated with the development of hepatocellular carcinoma (HCC). A chymotrypsin-like protease is responsible for cleavage of the SARS-CoV-2 viral polyprotein to form the RNA replicase-transcriptase complex, which plays a key role in the SARS-CoV-2 viral transcription and replication process.;

UNII : 911Z9PCQ5F;

InChIKey : ZVTDLPBHTSMEJZ-JSZLBQEHSA-N;

CAS number : 850876-88-9;

Molecule name : ITMN 191; RG 7227; ITMN-191; RG-7227;

NCI Metathesaurus CUI : CL1406067;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.